MedTrace Logo

Active Vitamin D Effect on Left Ventricular Hypertrophy

NCT00175149 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2015-12-08

No results posted yet for this study

Summary

Left ventricular hypertrophy (LVH) predicts mortality at start of dialysis. Prevention of of LVH is important. It is not known whether secondary hyperparathyroidism might induce LVH. In the present study patients are randomised to 1.25 dihydroxycholecalciferol or no treatment to study the effect on LVH.

Conditions

Interventions

DRUG

Alfacalcidiol

Alfacalcidiol are given to patientwith CKD 3-4 and secondary hyperparathyrodism. The PTH level is lowered to normal range. with increasing dose of alfacalcidiol and are followed for 6 month.

Sponsors & Collaborators

  • Per Ivarsen

    lead OTHER

Principal Investigators

  • Per Ivarsen, MD, PhD · Deparment of Renam Medicine C, Skejby Hospital

  • Per Ivarsen, MD, PhD · Deparment of Renal Medicine C, Skejby Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00175149 on ClinicalTrials.gov